Left ventricular hypertrophy after renal transplantation: New approach to a deadly disorder

Nephrology Dialysis Transplantation

Volumn 19, Issue 7, 2004, Pages 1682-1686

  Hernández, Domingo ^a,b  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b NONE   (Spain)

Author keywords

Cardiovascular mortality; Left ventricular hypertrophy; Renal transplantation

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SPIRONOLACTONE;

ANEMIA; ARTERIOVENOUS FISTULA; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; EDITORIAL; ENZYME POLYMORPHISM; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; IMMUNE DEFICIENCY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MORTALITY; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECIPIENT; REMISSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SURVIVAL; UREMIA;

ANIMALS; DIABETES COMPLICATIONS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION;

EID: 3242716694     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh283     Document Type: Editorial

References (35)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 [Suppl 3]: S112-S119
2. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease. Circulation 2003; 108: 2154-2169
3. De Lima JJG, Vieira MLC, Viviani LF et al. Long-term impact of renal transplantation on carotid artery properties and on ventricular hypertrophy in end-stage renal failure patients. Nephrol Dial Transplant 2002; 17: 645-651
4. Dählof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110
5. Koren MJ, Ulin RJ, Koren AT, Laragh JH, Devereux RB. Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens 2002; 15: 1021-1028
6. Stack AG, Saran R. Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States. Am J Kidney Dis 2002; 40: 1202-1210
7. Rigatto C, Foley R, Jeffery J, Negrijn C, Tribula C, Parfrey P. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol 2003; 14: 462-468
8. Amann K, Rychlik I, Miltenberger-Milteny G, Ritz E. Left ventricular hypertrophy in renal failure. Kidney Int 1998; 54 [Suppl 68]: S78-S85
9. Foley RN, Parfrey P, Harnett JD, Kent GM, Murray DC, Barré PE. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995; 5: 2024-2031
10. Rigatto C. Clinical epidemiology of cardiac disease in renal transplant recipients. Semin Dial 2003; 16: 106-110
11. Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993; 75: 977-984
12. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H. Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. Endocrinology 2000; 141: 1901-1904
13. Fishel RS, Eisenberg S, Shai S-Y, Redden RA, Bernstein KE, Berk BC. Glucocorticoids induce angiotensin-converting enzyme expression in vascular smooth muscle. Hypertension 1995; 25: 343-349
14. Vanrenterghem Y, Lebranchu Y, Hené R, Oppenheimer F, Ekberg H. Double-blind comparison of two corticosteroids regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000; 70: 1352-1359
15. Molkentin JD: Calcineurin and beyond cardiac hypertrophic signaling. Circ Res 2000; 87: 731-738
16. Sakata Y, Masuyama T, Yamamoto K et al. Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats. Circulation 2000; 102: 2269-2275
17. Shioi T, McMullen JR, Tarnavski O et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 2003; 107: 1664-1670
18. Davidson J, Wilkinson A, Dantal J et al. New-onset diabetes after transplantation: 2003 International Consensus Guidelines. Transplantation 2003; 75 [Suppl]: SS3-SS24
19. Zarich SW, Nesto RW. Diabetic cardiomyopathy. Am Heart J 1989; 118: 1000-1012
20. Dikow R, Ritz E. Cardiovascular complications in the diabetic patient with renal disease: an update in 2003. Nephrol Dial Transplant 2003; 18: 1993-1998
21. Barbagallo M, Gupta R, Resnick L. Cellular ions in NIDDM: relation of calcium to hyperglycemia and cardiac mass. Diabetes Care 1996; 19: 1393-1398
22. Candido R, Forbes JM, Thomas MC et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003; 92: 785-792
23. Copelli A, Giannarelli R, Mariotti R et al. Pancreas transplant alone determines early improvement of cardiovascular risk factors and cardiac function in type 1 diabetic patients. Transplantation 2003; 76: 974-976
24. Felicio JS, Ferreira SR. Plavnik FL et al. Effect of blood glucose on left ventricular mass in patients with hypertension and type 2 diabetes mellitus. Am J Hypertens 2000; 13: 1149-1154
25. Bunnapradist S, Cho YW, Cecka JM, Wilkinson A, Danovitch GM. Kidney allograft and patient survival in type 1 diabetic recipients of cadaveric kidney alone versus simultaneous pancreas/kidney transplant: a multivariate analysis of the UNOS database. J Am Soc Nephrol 2003; 14: 208-213
26. Schunkert H, Hense H-W, Holmer SR et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 1994; 330: 1634-1638
27. Hernández D, De la Rosa A, Barragán A et al. The ACE/DD genotype is associated with the extent of exercise-induced left ventricular growth in endurance athletes. J Am Coll Cardiol 2003; 42: 527-532
28. Hernández D, Lacalzada J, Rufino M et al. Prediction of left ventricular mass changes after renal transplantation by polymorphism of the angiotensin-converting-enzyme gene. Kidney Int 1997; 51: 1205-1211
29. Sakata Y, Yamamoto K, Masuyama T et al. Ventricular production of natriuretic peptides and ventricular structural remodeling in hypertensive heart failure. J Hypertens 2001; 19: 1905-1912
30. Mallamaci F, Zoccali C, Tripepi G et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 2001; 59: 1559-1566
31. Díez J, Querejeta R, López B, González A. Larman M, Ubago JLM. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002; 105: 2512-2517
32. Hernández D, Lacalzada J, Salido E et al. Regression of left ventricular hypertrophy by lisinopril after renal transplantation. Role of angiotensin-converting-enzyme gene polymorphism. Kidney Int 2000; 58: 889-897
33. Klingbeil AU, Muller HJ, Delles C, Fleischmann E, Schmieder RE. Regression of left ventricular hypertrophy by AT1 receptor blockade in renal transplant recipients. Am J Hypertens 2000; 13: 1295-1300
34. Tsutamoto T, Wada A, Maeda K et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001; 37: 1228-1233
35. Verdecchia P, Angeli F, Borgioni C et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003; 16: 895-899